January 7, 2014 Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone
January 6, 2014 Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
December 17, 2013 Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
December 14, 2013 Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013
December 7, 2013 New studies demonstrate that modified T cells are effective in treating blood-borne cancers
December 7, 2013 Kite Pharma’s Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin’s Lymphoma
September 28, 2013 Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
September 9, 2013 Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
August 8, 2013 Kite Pharma Appoints Leading Cancer Immunotherapy Experts to its Scientific Advisory Board
June 21, 2013 Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
May 15, 2013 Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
April 8, 2013 Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
March 19, 2013 Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
December 19, 2012 Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds
